Revolution Medicines (RVMD) to Release Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect Revolution Medicines to post earnings of ($0.88) per share for the quarter.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The firm had revenue of $1.00 million during the quarter, compared to analysts’ expectations of $0.81 million. The company’s quarterly revenue was down 73.8% on a year-over-year basis. During the same period last year, the firm posted ($0.92) earnings per share. On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Revolution Medicines Trading Up 0.2 %

RVMD opened at $50.50 on Thursday. The firm has a market cap of $8.44 billion, a price-to-earnings ratio of -13.47 and a beta of 1.43. Revolution Medicines has a 12 month low of $18.00 and a 12 month high of $51.10. The stock has a fifty day moving average price of $45.59 and a 200-day moving average price of $42.18.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Guggenheim boosted their target price on Revolution Medicines from $72.00 to $82.00 and gave the stock a “buy” rating in a research note on Monday. Jefferies Financial Group assumed coverage on Revolution Medicines in a research note on Monday, July 8th. They set a “buy” rating and a $63.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $61.00 target price on shares of Revolution Medicines in a research note on Thursday, October 24th. Oppenheimer boosted their target price on Revolution Medicines from $55.00 to $60.00 and gave the stock an “outperform” rating in a research note on Monday. Finally, HC Wainwright restated a “buy” rating and set a $56.00 target price on shares of Revolution Medicines in a research note on Monday, August 12th. Eleven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $56.75.

Insider Buying and Selling at Revolution Medicines

In other news, insider Stephen Michael Kelsey sold 16,666 shares of the company’s stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $49.49, for a total value of $824,800.34. Following the sale, the insider now owns 264,408 shares in the company, valued at $13,085,551.92. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Jack Anders sold 10,000 shares of Revolution Medicines stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $50.30, for a total transaction of $503,000.00. Following the completion of the transaction, the chief financial officer now directly owns 98,932 shares of the company’s stock, valued at $4,976,279.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen Michael Kelsey sold 16,666 shares of Revolution Medicines stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $49.49, for a total transaction of $824,800.34. Following the transaction, the insider now directly owns 264,408 shares of the company’s stock, valued at approximately $13,085,551.92. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 127,866 shares of company stock worth $6,355,624. 8.00% of the stock is currently owned by insiders.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.